Home Prescient Therapeutics Limited (ASX: PTX)

Prescient Therapeutics Limited (ASX: PTX)

    Journey of Prescient Therapeutics in 2019

    Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company that works on mutation causing cancer. The existing product portfolio of the company includes...

    Prescient Therapeutics’ Cancer Trials Backed By A Robust Product Portfolio

    Clinical stage oncology company Prescient Therapeutics Limited (ASX: PTX) is in the process of developing a breakthrough to traditional therapies by its novel drug...

    Prescient Therapeutics starts Phase 1b clinical trial of its unique inhibitor PTX-100

    On 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b trial of its second targeted anti-cancer drug PTX-100...

    Prescient Therapeutics’ drug candidates addressing the mutations causing cancer

    Clinical-Stage oncology company, Prescient Therapeutics Limited (ASX: PTX) bases the foundation of its business model on the ground-breaking technology that addresses the mutations causing...

    All that investors need to know about clinical stage oncology company, Prescient Therapeutics

    Prescient Therapeutics Limited (ASX: PTX), based in South Melbourne, Australia, is an oncology company (clinical-stage) that develops novel drugs and targeted therapies to treat...

    Prescient Therapeutics Announces The Receipts of R&D Tax Rebate

    On 15 January 2019, Prescient Therapeutics Limited (ASX: PTX) announced that the company had received Tax Incentive rebate on research and development for the...

    Recent News